EG 427

EG 427 is a Paris-based gene therapy startup pioneering the use of engineered, non-replicative Herpes Simplex Virus 1 (HSV-1) vectors as a DNA medicine platform. The company aims to tackle localized chronic diseases by enabling precise, long-term, and safe transgene expression, initially targeting disorders of the peripheral nervous system. It has secured non-dilutive funding from French government entities and is building its pipeline and manufacturing capabilities. EG 427 is currently in a pre-clinical development stage, actively recruiting to advance its lead program for bladder disorders.

Non-replicative Herpes Simplex Virus 1 (nrHSV-1) vector platform engineered for large gene capacity, targeted expression in specific neuronal subsets via specific promoters, and safe, durable, redosable administration.

EG 427 competes in the neurology and urology gene therapy space against companies using AAV vectors (e.g., Neurocrine, Axovant, Lysogene) and other modalities. Its key differentiator is the use of HSV-1 vectors for potentially superior neuronal targeting, large gene capacity, and redosability, but it must prove these advantages clinically.